Tanager Wealth Management LLP Sells 186 Shares of Thermo Fisher Scientific Inc. $TMO

Tanager Wealth Management LLP cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 839 shares of the medical research company’s stock after selling 186 shares during the quarter. Tanager Wealth Management LLP’s holdings in Thermo Fisher Scientific were worth $340,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. CBIZ Investment Advisory Services LLC boosted its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $37,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $531.69 on Thursday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $616.57. The company has a 50-day simple moving average of $480.27 and a 200 day simple moving average of $447.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $200.77 billion, a PE ratio of 30.75, a price-to-earnings-growth ratio of 2.63 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the company posted $5.37 earnings per share. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 over the last quarter. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on TMO shares. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, September 7th. Fifteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $583.53.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.